BioAtla (BCAB) Research Hub

BioAtla (BCAB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-08, shares last closed at 1.26 USD (-4.55%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.08, market cap 0.00B. This hub links to the full technical, earnings and options research available for BCAB.

Last updated 2026-09-08 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close1.26 USD (-4.55%)
52-week range1.07 USD – 4.73 USD
Trend regimeRange
14-day RSI20.1 (Oversold)
Trailing P/E-0.08
Market cap0.00B
Dividend yield0.00%
Next earnings2026-08-06

Available research for BCAB

Earnings

BCAB earnings date and last-quarter result: next report 2026-08-06, last quarter beat, P/E -0.08. Updated 2026-07-23.

Options: Covered Call

Covered Call on BCAB: how it works, illustrative setup around the real 1.26 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on BCAB: how it works, illustrative setup around the real 1.26 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on BCAB: how it works, illustrative setup around the real 1.26 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

BCAB technical analysis: range, last 1.26 USD, RSI 20.1, 52w range 1.07 USD–4.73 USD, real support/resistance. Updated 2026-09-08.

More on SniperIQ

Frequently asked questions

What sector is BCAB in?

BioAtla (BCAB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is BCAB in an uptrend or downtrend?

As of 2026-09-08, BCAB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is BCAB's trailing P/E ratio?

BCAB's trailing P/E is -0.08, with a market cap of 0.00B. See the earnings research page for full valuation detail.

When does BCAB next report earnings?

BCAB is next scheduled to report earnings on 2026-08-06.